Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Karyopharm Therapeutics Inc.
Headquarters: Newton, MA, United States of America
Website: http://www.karyopharm.com
Year Founded: 2008
Status: Public
Industry Sector: HealthTechnology
CEO: Richard A. Paulson, MBA
Number Of Employees: 279
Enterprise Value: $168,197,947
PE Ratio: -0.25
Exchange/Ticker 1: NASDAQ:KPTI
Exchange/Ticker 2: N/A
Latest Market Cap: $32,485,802
BioCentury | Jan 4, 2025
Management Tracks
Four companies announce new CFOs
Plus: Jia joins Grit Bio and Riley joins Avalo
BioCentury | Nov 21, 2024
Management Tracks
Amgen names Howard Chang head of research and CSO
Plus: Head of R&D Blackman retires from Day One, and updates from Karyopharm and L.E.K.
BioCentury | Nov 14, 2023
Management Tracks
Huntsman to head commercial at Madrigal
Plus: Robbins named CEO at Incendia, and updates from Nereid, Affini-T and Geneoscopy
BioCentury | Aug 12, 2023
Regulation
Aug. 11 Quick Takes: Janssen gains prostate cancer approval
Plus: Atreca scraps lead program, turns to ADCs and updates from ALX Oncology, Hansoh-Antengene, Foghorn, Galera, Cascade
BioCentury | Dec 6, 2022
Product Development
Dec. 5 Quick Takes: Nkarta reports 70% complete response
Plus: Verve falls on clinical hold and updates from J&J, Affinia, TherapeuticsMD, Biogen and more
BioCentury | Jul 22, 2022
Finance
July 21 Quick Takes: Verve raises $225M on back of Vertex deal, clinical milestone
Plus Biogen resolving kickback claim, ARS reverse-merging with Silverback and more
BioCentury | Jun 17, 2022
Product Development
June 16 Quick Takes: BioInvent gets $25M in mAb discovery deal with Exelixis
Plus Biogen returns Karyopharm ALS asset and updates from Akero, Rhythm and more
BioCentury | Mar 29, 2022
Management Tracks
Rangwala to be CMO at Karyopharm
Plus Jones becomes CFO at Sense, and updates from Enzo, Dice and more
BioCentury | Mar 21, 2022
Management Tracks
Mahal now COO at Jasper
Plus Crinetics recruits a chief business officer and updates from Ribometrix and Osler
BioCentury | Mar 2, 2022
Product Development
March 1 Quick Takes: Setbacks in C. diff for Pfizer, Finch
Plus Karyopharm tumbles, Epizyme cuts, and updates from Alnylam, Novavax, Gilead and more
Items per page:
1 - 10 of 160